Moores Cancer Center

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Retrieved on: 
Tuesday, February 13, 2024

REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd.("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it convened a Scientific Advisory Board (SAB) focusing the discussions on NT219’s indication in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Key Points: 
  • “Their recognition of the critical unmet need in recurrent and metastatic head and neck cancer provides further support and momentum to our development program.
  • Now that we have determined the recommended Phase 2 dose, we are prepared to move to our next phase of development.
  • We look forward to the head and neck cancer SAB’s continued guidance and support.”
    Head & Neck Cancer SAB Members Include:
    Douglas Adkins, MD – Dr. Adkins is a Professor of Medicine and Director, Head and Neck and Thyroid Medical Oncology, at the Siteman Cancer Center, Washington University School of Medicine.
  • He is a nationally recognized expert in head and neck cancer known for his commitment to advancing patient care through clinical research.

Bioluminescence Ventures Reveals Partners and Investment Management Team

Retrieved on: 
Friday, January 5, 2024

Bioluminescence Ventures (“BLV”), a biotech venture firm investing in next-generation medicines, today revealed its initial team of Partners, whose collective experience and expertise spans preclinical research, translational science, clinical development, medical affairs, regulatory, commercial strategy, business development, and strategic investment banking functions across therapeutic areas.

Key Points: 
  • Bioluminescence Ventures (“BLV”), a biotech venture firm investing in next-generation medicines, today revealed its initial team of Partners, whose collective experience and expertise spans preclinical research, translational science, clinical development, medical affairs, regulatory, commercial strategy, business development, and strategic investment banking functions across therapeutic areas.
  • Every day, I feel honored and lucky to be working with such talented, mission-driven, and caring people.”
    Chloe Kim, Ph.D. joined Bioluminescence Ventures as a Partner in 2022.
  • Negin Mokhtari, Ph.D. joined Bioluminescence Ventures as a Partner in 2023 and brings a blend of scientific expertise, operational experience, and investment skills to the firm.
  • Prior to joining Bioluminescence Ventures, Dr. Mokhtari was part of the investment team at Genoa Ventures, focusing on the convergence of biology and technology, and serving on the board of multiple companies.

Leading Academic Medical Centers Join Biological Dynamics’ ExoLuminate™ Study, Expanding Enrollment for Early Pancreatic Cancer Detection

Retrieved on: 
Tuesday, December 5, 2023

Biological Dynamics, Inc. , a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.
  • Known as a “silent killer,” approximately 80% of pancreatic cancer patients discover the disease in late stages when it has already spread and cannot be surgically removed.
  • “Currently, there is no standard early detection test for pancreatic cancer, resulting in an unmet need for innovative solutions to help solve this challenging disease,” said Harmeet Dhani, MD, MSc, Medical Director at Biological Dynamics and Principal Study Investigator.
  • “Collaborating with these cutting-edge institutions expands our work with some of the top cancer researchers in the world.

Revolution Medicines Completes Acquisition of EQRx

Retrieved on: 
Thursday, November 9, 2023

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.

Key Points: 
  • Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs
    REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.
  • Through the acquisition, Revolution Medicines expects to add approximately $1.1 billion in net cash proceeds to its balance sheet, after estimated post-closing EQRx wind-down and transition costs.
  • Each share of common stock of EQRx issued has been converted into the right to receive 0.1112 shares of common stock of Revolution Medicines.
  • EQRx common stock has ceased trading on the Nasdaq Global Market and all EQRx programs are being wound down.

CancerVAX CEO Ryan Davies Discusses Cancer Drug Development with Dr. Ezra Cohen

Retrieved on: 
Thursday, November 2, 2023

LEHI, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago.

Key Points: 
  • LEHI, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago.
  • “I got into medicine to make a difference in people’s lives, said Dr. Cohen.
  • “I realized that cancer patients needed more focus and more attention than other patient groups.
  • Cohen is a lovely man with incredible experience and noble intentions,” said CancerVax CEO, Ryan Davies.

ATCC Appoints Dr. Alfredo Molinolo to Its Board of Directors

Retrieved on: 
Thursday, November 2, 2023

“Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.

Key Points: 
  • “Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.
  • Dr. Molinolo earned both his PhD in oncology and MD in medicine from the University of Buenos Aires in Argentina.
  • Dr. Molinolo has received several awards and has written numerous publications about breast, oral, and head and neck cancer.
  • “Serving on the Board is an opportunity for me to make further contributions to science,” said Dr. Molinolo.

Rady Children's Researcher Awarded $4 Million

Retrieved on: 
Tuesday, October 10, 2023

SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- The National Institutes of Health (NIH) and the National Cancer Institute (NCI) recently awarded a $4 million Research Project Grant (RO1) to Paula Aristizabal, MD, MAS, pediatric oncologist at Rady Children's Hospital-San Diego and Associate Professor of Pediatrics in Pediatric Hematology/Oncology at the University of California San Diego and Moores Cancer Center to expand a pilot program aimed at improving diverse participation in pediatric cancer clinical trials. 

Key Points: 
  • Curebound , a San Diego-based philanthropic organization that raises and invests strategic funding in translational cancer research projects, funded the program with a $125,000 medical grant.
  • Based on the success of that program, Dr. Aristizabal and her team were awarded the NIH/NCI grant to implement a culturally and linguistically tailored peer-navigation intervention to increase minority participation in pediatric cancer clinical trials.
  • ‌About Rady Children's Hospital-San Diego:
    ‌ Rady Children's Hospital-San Diego is the largest children's hospital on the West Coast and one of the nation's top pediatric health care systems.
  • Rady Children's is a nonprofit organization that relies on donations to support its mission.

CureScience™ Institute Fall-Spring Scholars Bioinformatics and Machine Learning Program

Retrieved on: 
Tuesday, September 19, 2023

The Fall-Spring Scholars Bioinformatics and Machine Learning Program invites students with a strong interest in science to fill out the online application on the CureScience™ Institute website.

Key Points: 
  • The Fall-Spring Scholars Bioinformatics and Machine Learning Program invites students with a strong interest in science to fill out the online application on the CureScience™ Institute website.
  • Students will have the opportunity to interact with CureScience scientists to conduct original, innovative research projects in areas such as: cancer biology, drug design, computational biology, infectious disease, machine learning, artificial intelligence, and more.
  • He is a world-known expert in structural biology, molecular modeling, bioinformatics, and using AI for drug design and treatment.
  • She has authored over 50 scientific papers, three books and eight book chapters, and 13 patents.

GBW Attorneys Obtain Groundbreaking $39 Million Jury Verdict Against the Regents of The University of California for Doctor's Whistleblower Retaliation

Retrieved on: 
Monday, August 14, 2023

The jury unequivocally supported Dr. Kevin Murphy in his retaliation case against the UC Regents in San Diego Superior Court.

Key Points: 
  • The jury unequivocally supported Dr. Kevin Murphy in his retaliation case against the UC Regents in San Diego Superior Court.
  • Dr. Murphy, age 55, contended that the university diverted these funds to the Moores Cancer Center without obtaining his consent.
  • When he acted as a whistleblower to expose this wrongdoing, he faced severe backlash and ultimately lost his job.
  • The Regents of The University of California
    View original content to download multimedia: https://www.prnewswire.com/news-releases/gbw-attorneys-obtain-groundbrea...
    SOURCE Greene Broillet & Wheeler, LLP

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

Retrieved on: 
Thursday, June 15, 2023

On the webcast Mr. David Urso will provide an update on the pending merger and an overview of the combined company, which joins the expertise and resources of MEI and Infinity to advance a robust pipeline of three clinical-stage oncology drug candidates.

Key Points: 
  • On the webcast Mr. David Urso will provide an update on the pending merger and an overview of the combined company, which joins the expertise and resources of MEI and Infinity to advance a robust pipeline of three clinical-stage oncology drug candidates.
  • The combined company’s development pipeline consists of three differentiated programs.
  • You can access the video webcast under the investor relations section of MEI's website on the "Events and Presentation" page at www.meipharma.com , or under the investor relations page of Infinity’s website on its “Events and Presentation” page at www.infi.com .
  • The pre-recorded video webcast will be archived for at least 30 days after the conclusion of the event.